Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 3/20 | 0.55 |
| ▸ | CTSC | P53634 | 2/20 | 0.55 |
| ▸ | MEN1 | O00255 | 2/20 | 0.54 |
| ▸ | XIAP | P98170 | 1/20 | 0.53 |
| ▸ | GAA | P10253 | 1/20 | 0.52 |
| ▸ | MMP8 | P22894 | 1/20 | 0.51 |
| ▸ | MME | P08473 | 1/20 | 0.51 |
| ▸ | POLB | P06746 | 1/20 | 0.51 |
| ▸ | EGFR | P00533 | 2/20 | 0.51 |
| ▸ | SRC | P12931 | 1/20 | 0.51 |
| ▸ | ANPEP | P15144 | 1/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.50 |
| ▸ | MAPT | P10636 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2742291 | 1.00 | KMT2A (0.55) | KMT2ACTSCMEN1XIAPGAA | |
| SCHEMBL12240253 | 1.00 | KMT2A (0.55) | KMT2ACTSCMEN1XIAPGAA | |
| SCHEMBL15623811 | 0.88 | FNTA (0.52) | KMT2ACTSCMEN1POLB | |
| SCHEMBL8549002 | 0.87 | SPHK1 (0.57) | KMT2AMMP8MMEEGFRSRC | |
| SCHEMBL8251354 | 0.85 | SPHK1 (0.51) | KMT2ACTSCMEN1ANPEP | |
| SCHEMBL1697377 | 0.84 | MMP8 (0.53) | KMT2AGAAMMP8MMEEGFR | |
| SCHEMBL7413310 | 0.84 | ALPI (0.61) | KMT2ACTSCXIAPMMP8MME | |
| SCHEMBL5653978 | 0.84 | MMP8 (0.53) | KMT2AGAAMMP8MMEEGFR | |
| SCHEMBL3114367 | 0.84 | ALPI (0.61) | KMT2ACTSCXIAPMMP8MME | |
| SCHEMBL47278 | 0.84 | MMP8 (0.53) | KMT2AGAAMMP8MMEEGFR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9771317-B2 | Process for preparing lacosamide and related compounds | CAMBREX KARLSKOGA AB (SE) | 2017-09-26 | — | — | US | disclosed |
| US-20150299105-A1 | NEW PROCESS | CAMBREX KARLSKOGA AB (SE) | 2015-10-22 | — | — | US | disclosed |
| US-8946476-B2 | Process for the preparation of amino acid derivatives | UCB PHARMA GMBH (DE) | 2015-02-03 | — | — | US | disclosed |
| US-8378142-B2 | Intermediate compounds and their use in preparation of lacosamide | RANBAXY LABORATORIES LIMITED (IN) | 2013-02-19 | — | — | US | disclosed |
| US-20120004452-A1 | INTERMEDIATE COMPOUNDS AND THEIR USE IN PREPARATION OF LACOSAMIDE | RANBAXY LABORATORIES LIMITED (IN) | 2012-01-05 | — | — | US | disclosed |
| US-20120004462-A1 | INTERMEDIATE COMPOUNDS AND THEIR USE IN PREPARATION OF LACOSAMIDE | RANBAXY LABORATORIES LIMITED (IN) | 2012-01-05 | — | — | US | disclosed |
| US-20110263899-A1 | Novel Process for the Preparation of Amino Acid Derivatives | UCB PHARMA GMBH (DE) | 2011-10-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150299105-A1 | NEW PROCESS | SLC6A11, SLC6A1, SCN11A | KMT2A 1845/4885CTSC 1080/4885MEN1 4125/4885 |
| US-20120004452-A1 | INTERMEDIATE COMPOUNDS AND THEIR USE IN PREPARATION OF LACOSAMIDE | HDAC2, HDAC5, SCN5A | KMT2A 178/4885CTSC 1854/4885MEN1 580/4885 |
| US-20110263899-A1 | Novel Process for the Preparation of Amino Acid Derivatives | BCAT2, DNPEP, NPEPPS | KMT2A 514/4885CTSC 485/4885MEN1 3770/4885 |
| US-20120004462-A1 | INTERMEDIATE COMPOUNDS AND THEIR USE IN PREPARATION OF LACOSAMIDE | HDAC2, HDAC5, SCN5A | KMT2A 178/4885CTSC 1854/4885MEN1 580/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.